Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 466 | 84 | 372 |
| Samples | 412 | 76 | 328 |
| Peptides | 339 | 49 | 290 |
Function
IPO7 · Importin 7
The importin-alpha/beta complex and the GTPase Ran mediate nuclear import of proteins with a classical nuclear localization signal. The protein encoded by this gene is a member of a class of approximately 20 potential Ran targets that share a sequence motif related to the Ran-binding site of importin-beta. Similar to importin-beta, this protein prevents the activation of Ran's GTPase by RanGAP1 and inhibits nucleotide exchange on RanGTP, and also binds directly to nuclear pore complexes where it competes for binding sites with importin-beta and transportin. This protein has a Ran-dependent transport cycle and it can cross the nuclear envelope rapidly and in both directions. At least four importin beta-like transport receptors, namely importin beta itself, transportin, RanBP5 and RanBP7, directly bind and import ribosomal proteins. [provided by RefSeq, Jul 2008].
Isoforms & Proteins
2 transcripts · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
Gene Properties
Recurrent Mutations
All 333 amino-acid changes on canonical ENST00000379719 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in IPO7 · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in IPO7 – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| T-Lymphoblastic Leukemia | 9/40 22% | 0/0 0% |
| T-Cell Non-Hodgkins Lymphoma | 2/26 8% | 0/0 0% |
| Chronic Myelogenous Leukemia | 1/25 4% | 0/0 0% |
| Oral Cavity Carcinoma | 2/54 4% | 0/0 0% |
| Endometrial Carcinoma | 0/42 0% | 20/612 3% |
| Cervical Carcinoma | 4/35 11% | 9/422 2% |
| Melanoma | 4/210 2% | 48/1899 3% |
| Bladder Carcinoma | 0/58 0% | 22/956 2% |
| Colorectal Carcinoma | 12/143 8% | 47/3239 1% |
| Non-Small Cell Lung Carcinoma | 11/304 4% | 15/1390 1% |
| Gastric Carcinoma | 2/74 3% | 21/1809 1% |
| Acute Myeloid Leukemia | 1/90 1% | 0/0 0% |
| Thyroid Gland Carcinoma | 1/45 2% | 15/1592 1% |
| Squamous Cell Lung Carcinoma | 0/57 0% | 8/810 1% |
| Ovarian Carcinoma | 5/109 5% | 5/998 0% |
| Esophageal Squamous Cell Carcinoma | 2/51 4% | 21/2550 1% |
| Adrenocortical Carcinoma | 0/3 0% | 1/112 1% |
| Neuroendocrine Tumour | 4/154 3% | 2/577 0% |
| Other Solid Cancers | 2/94 2% | 11/1515 1% |
| Small Cell Lung Carcinoma | 0/9 0% | 6/752 1% |
| Hodgkins Lymphoma | 0/16 0% | 1/122 1% |
| Hepatocellular Carcinoma | 0/46 0% | 16/2210 1% |
| Head and Neck Carcinoma | 1/85 1% | 9/1574 1% |
| Other Sarcomas | 0/69 0% | 4/699 1% |
| Esophageal Carcinoma | 0/23 0% | 4/769 1% |
| Glioma | 0/52 0% | 11/2127 1% |
| Breast Carcinoma | 3/144 2% | 13/3264 0% |
| Kidney Carcinoma | 1/85 1% | 7/1862 0% |
| Biliary Tract Carcinoma | 0/54 0% | 4/950 0% |
| B-Cell Non-Hodgkins Lymphoma | 3/88 3% | 6/2534 0% |
Mutation Distribution
Where IPO7 is mutated · all tissues, split by cell line vs tissue
How many mutations in IPO7 were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
GTEx Expression
Median TPM across 54 healthy tissues
Median gene expression (TPM) in normal, non-cancer human tissues from the GTEx project.
Useful for judging tumour specificity – a strong neoantigen target ideally comes from a gene with low expression in healthy tissues.
Scroll or drag the mini-axis below the chart to browse all tissues.
Mutations
All 466 mutations in IPO7
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|